图书简介
This book discusses specific immune cell regulatory pathway(s), immune cell types, or other mechanisms involved in host responses to tuberculosis that can be potentially targeted for host/directed therapy (HDT). The pathways/mechanisms investigated are either protective / thus calling for pathway/factor enhancing drugs / or maladaptive / thus calling for pathway/factor inhibitory drugs. Discovery and development (pre/clinical and clinical) of candidate HDT agents will also be elucidated, as well as approaches for HDT of other diseases. The benefit to the reader will derive from learning about the biology of multiple host pathways involved in health and disease, how these pathways are disrupted or dysregulated during tuberculosis, and which druggable targets exist in these pathways. This book provides the reader with a roadmap of current and future directions of HDT against tuberculosis. Since the host pathways/factors involved in protective or maladaptive responses to tuberculosis are not disease/specific, information learned from the context of tuberculosis likely will be relevant to other infectious and non/infectious diseases.
Section 1: Introduction Chapter 1: Introduction: An overview of host/directed therapies for tuberculosis Daniel Frank, Robert Mahon Section 2: Targeting immunometabolism Chapter 2: Sirtuin deacetylases: Linking Mycobacterial infection and host metabolism Lorissa Smulan, Hardy Kornfeld, and Amit Singhal Chapter 3: The mammalian target of rapamycin complex 1 (mTORC1): an ally of M. tuberculosis in host cells Natalie Bruiners, Valentina Guerrini, Maria Laura Gennaro Chapter 4: HIF/1 as a potential therapeutic target for tuberculosis treatment Qingkui Jiang, Maria Laura Gennaro, Lanbo Shi Chapter 5: Nuclear receptors in host/directed therapies against tuberculosis Eun/Kyeong Jo Section 3: Enhancing anti/mycobacterial mechanisms Chapter 6: Autophagy as a target for host/directed therapy against tuberculosis Surbhi Verma, Raman Deep Sharma and Dhiraj Kumar Chapter 7: Metformin: a leading HDT candidate for TB Amit Singhal and Hardy Kornfeld Chapter 8: Statins as host/directed therapy for tuberculosis Noton K. Dutta, Petros C. Karakousis Chapter 9: Antimycobacterial attributes of mitochondria: An insight into host defense mechanisms Rikesh K Dubey, Apoorva Narain Section 4: Targeting immune cells Chapter 10: Conventional and unconventional lymphocytes in immunity against Mycobacterium tuberculosis Paula Ruibal, Tom H.M. Ottenhoff, Simone A. Joosten Chapter 11: Targeting inhibitory cells such as Tregs and MDSCs in the tuberculous granuloma Sadiya Parveen, John R. Murphy, and William R. Bishai Chapter 12: Targeting suppressor T cells Leanie Kleynhans, Gerhard Walzl Chapter 13: Neutrophil/mediated mechanisms as targets for host/directed therapies against tuberculosis Tobias Dallenga, Ulrich E. Schaible Chapter 14: Type I interferon and interleukin/1 driven inflammatory pathways as targets for HDT in tuberculosis Katrin D. Mayer/Barber, Christopher M. Sassetti Chapter 15: Mucosal/associated invariant and V 9V 2 T cells Charles K. Vorkas, Michael S. Glickman Chapter 16: Airway epithelial cells Angelica M. Olmo/Fontanez, Jordi B. Torrelles Section 5: Preclinical models for assessing HDTs Chapter 17: In vitro models of human granuloma formation to analyze host/directed therapies Liku B. Tezera, Michaela T. Reichmann, Basim Al Shammari, Paul T. Elkington Chapter 18: C3HeB/FeJ as a key mouse strain for testing host/directed therapies against tuberculosis Pere/Joan Cardona, Cristina Vilaplana Chapter 19: The Rabbit Model for Assessing Host/Directed Therapies for Tuberculosis Selvakumar Subbian, Gilla Kaplan Section 6: Clinical trials of HDTs and special considerations for study endpoints Chapter 20: Clinical trials of TB/HDT candidates Robert S. Wallis Chapter 21: Outcomes for clinical trials of host/directed therapies for tuberculosis Akshay N. Gupte, Sara C. Auld, William N. Checkley, Gregory P. Bisson Chapter 22: Pharmacological considerations for clinical trials of host/directed therapies for tuberculosis Elisa H. Ignatius, Kelly E. Dooley
Trade Policy 买家须知
- 关于产品：
- ● 正版保障：本网站隶属于中国国际图书贸易集团公司，确保所有图书都是100%正版。
- ● 环保纸张：进口图书大多使用的都是环保轻型张，颜色偏黄，重量比较轻。
- ● 毛边版：即书翻页的地方，故意做成了参差不齐的样子，一般为精装版，更具收藏价值。
关于退换货：- 由于预订产品的特殊性，采购订单正式发订后，买方不得无故取消全部或部分产品的订购。
- 由于进口图书的特殊性，发生以下情况的，请直接拒收货物，由快递返回：
- ● 外包装破损/发错货/少发货/图书外观破损/图书配件不全（例如：光盘等）
并请在工作日通过电话400-008-1110联系我们。
- 签收后，如发生以下情况，请在签收后的5个工作日内联系客服办理退换货：
- ● 缺页/错页/错印/脱线
关于发货时间：- 一般情况下：
- ●【现货】 下单后48小时内由北京（库房）发出快递。
- ●【预订】【预售】下单后国外发货，到货时间预计5-8周左右，店铺默认中通快递，如需顺丰快递邮费到付。
- ● 需要开具发票的客户，发货时间可能在上述基础上再延后1-2个工作日（紧急发票需求，请联系010-68433105/3213）；
- ● 如遇其他特殊原因，对发货时间有影响的，我们会第一时间在网站公告，敬请留意。
关于到货时间：- 由于进口图书入境入库后，都是委托第三方快递发货，所以我们只能保证在规定时间内发出，但无法为您保证确切的到货时间。
- ● 主要城市一般2-4天
- ● 偏远地区一般4-7天
关于接听咨询电话的时间：- 010-68433105/3213正常接听咨询电话的时间为：周一至周五上午8：30～下午5：00，周六、日及法定节假日休息，将无法接听来电，敬请谅解。
- 其它时间您也可以通过邮件联系我们：customer@readgo.cn,工作日会优先处理。
关于快递：- ● 已付款订单：主要由中通、宅急送负责派送，订单进度查询请拨打010-68433105/3213。
本书暂无推荐
本书暂无推荐
